Prostatic acid Phosphatase/ACPP Protein-VLP, Human (386a.a, HEK293, His)

Prostatic acid phosphatase (ACPP) operates as a versatile tyrosine phosphatase under acidic conditions (pH 4-6), dephosphorylating various substrates, including orthophosphate monoesters. With lipid phosphatase activity, ACPP inactivates lysophosphatidic acid in seminal plasma. In prostate cancer, it acts as a tumor suppressor by dephosphorylating ERBB2, deactivating MAPK signaling, and controlling cancer-related processes. ACPP also exhibits ecto-5'-nucleotidase activity in dorsal root ganglion neurons, suggesting a role in pain modulation by generating adenosine from AMP. Prostatic acid Phosphatase/ACPP Protein-VLP, Human (386a.a, HEK293, His) is the recombinant human-derived Prostatic acid Phosphatase/ACPP protein-VLP, expressed by HEK293, with N-10*His labeled tag. The total length of Prostatic acid Phosphatase/ACPP Protein-VLP, Human (386a.a, HEK293, His) is 386 a.a., with molecular weight of 47.5 kDa.

Prostatic acid phosphatase (ACPP) is a non-specific tyrosine phosphatase that operates under acidic conditions (pH 4-6), demonstrating its versatility in dephosphorylating a diverse array of substrates, including alkyl, aryl, and acyl orthophosphate monoesters, as well as phosphorylated proteins. Notably, ACPP exhibits lipid phosphatase activity, contributing to the inactivation of lysophosphatidic acid in seminal plasma. Functioning as a tumor suppressor in prostate cancer, ACPP plays a crucial role in dephosphorylating ERBB2 and deactivating MAPK-mediated signaling, thereby exerting control over cellular processes implicated in cancer progression. Beyond its tyrosine phosphatase activity, ACPP showcases ecto-5'-nucleotidase activity in dorsal root ganglion neurons, generating adenosine from AMP. This additional function suggests a role in pain modulation, where adenosine acts as a pain suppressor, emphasizing the multifaceted nature of ACPP in cellular processes.

Human

HEK293

N-10*His

P15309 (K33-I418)

55  [NCBI]

KELKFVTLVFRHGDRSPIDTFPTDPIKESSWPQGFGQLTQLGMEQHYELGEYIRKRYRKFLNESYKHEQVYIRSTDVDRTLMSAMTNLAALFPPEGVSIWNPILLWQPIPVHTVPLSEDQLLYLPFRNCPRFQELESETLKSEEFQKRLHPYKDFIATLGKLSGLHGQDLFGIWSKVYDPLYCESVHNFTLPSWATEDTMTKLRELSELSLLSLYGIHKQKEKSRLQGGVLVNEILNHMKRATQIPSYKKLIMYSAHDTTVSGLQMALDVYNGLLPPYASCHLTELYFEKGEYFVEMYYRNETQHEPYPLMLPGCSPSCPLERFAELVGPVIPQDWSTECMTTNSHQVLKVIFAVAFCLISAVLMVLLFIHIRRGLCWQRESYGNI

47.5 kDa

Greater than 90% as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.